Biotech | January 25, 2022
SQI Diagnostics inks pact with UK-Based Owlstone Medical
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
The company has been manufacturing masks since the Covid-19 outbreak in 2020
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
The country is sixth among the most affected countries by active cases
UCB plans to submit regulatory applications in Q3 2022
Go-ahead for pivotal clinical trial which is expected to commence by March
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
However, these won’t be available at the nearest chemist store soon
Subscribe To Our Newsletter & Stay Updated
